International Union of Immunological Societies

Progyny, Inc. Announces Third Quarter 2023 Results

Retrieved on: 
Mardi, novembre 7, 2023
Adjustment, Female, International Union of Immunological Societies, Genetic testing, Event, GAAP, ART, Male, Growth, IVF, ID, Security (finance)

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a leading benefits management company specializing in fertility and family building benefits solutions, today announced its financial results for the three-month period ended September 30, 2023 (“the third quarter of 2023”) as compared to the three-month period ended September 30, 2022 (“the third quarter of 2022” or “the prior year period”).

Key Points: 
  • ** Represents the member utilization rate for all services, including, but not limited to, ART cycles, initial consultations, IUIs, and genetic testing.
  • For purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period.
  • Progyny will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) today, November 7, 2023, to discuss its financial results.
  • A replay of the call will be available until November 14, 2023 at 6:00 P.M. Eastern Time by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international) and entering passcode 265484.

Olive Fertility Centre Nurse Educator Acknowledged at Canadian Fertility and Andrology Society (CFAS) 2023 Meeting

Retrieved on: 
Lundi, septembre 25, 2023
Olive, Test management, Reproductive medicine, University, Professional, LGBTQ2, Woman, Medicine, Research, Mentorship, Multimedia, BSN, IVF, Fertility, Patient, International Union of Immunological Societies, Nursing, Entrepreneurship, NIPT, Hospital

VANCOUVER, BC, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting. This award serves as a recognition of her dedication and exceptional work in the field of reproductive medicine.

Key Points: 
  • Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting.
  • VANCOUVER, BC, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is delighted to announce that Paula Anderson, BSN, Nurse Educator at Olive Fertility Centre Vancouver, has been honoured with the prestigious Carole Rheaume Award at the Canadian Fertility and Andrology Society (CFAS) 2023 Meeting.
  • The Canadian Fertility and Andrology Society (CFAS) is Canada's premier national organization of professionals specializing in reproductive medicine.
  • She has become a passionate educator at Olive Fertility Centre, nurturing and mentoring the new generations of fertility nurses.

DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board

Retrieved on: 
Mardi, mars 14, 2023
Oncology, Health, Other Health, Clinical Trials, Research, Science, Biotechnology, Macrophage, Inflammation, University, Algiers, IUIS, International Union of Immunological Societies, University of Paris, Mount Sinai School, Disease, Homeostasis, Icahn School of Medicine at Mount Sinai, Paris Diderot University, Multimedia, National academy, Mount Sinai, Coronavirus Scientific Advisory Board, DEM, Cancer, B cell, Stanford University, Vaccine, Medicine

DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and macrophages to eliminate cancer, today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.

Key Points: 
  • DEM BioPharma, Inc. (DEM Bio), an immune-oncology company developing therapies that target signals on cancer cells and macrophages to eliminate cancer, today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.
  • Dr. Merad is credited with identifying the tissue resident macrophage lineage and revealing its distinct role in organ physiology and pathophysiology.
  • Dr. Merad is the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.
  • She holds a Master’s degree in biotechnology and a Ph.D. in immunology from Stanford University and University Paris VII.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

Retrieved on: 
Mercredi, décembre 7, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Tao, Vall, Helen, Immune-mediated inflammatory diseases, Federalisation of the European Union, Ephraim, COVID-19, University of Barcelona, Natural killer T cell, Teaching hospital, Phosphorylation, Virus, Bristol Myers Squibb, Partnership, American Cancer Society, Inflammation, University, Hospital, University School, Machine learning, National academy, EFIS, MD, Signal transduction, Howard Hughes Medical Institute, Science, DNS, University of California, San Francisco, Faculty, Immunology, Homeostasis, Immune system, Microbiota, International Union of Immunological Societies, Patient, Immunotherapy, Research, Journal, Tyrosine, UCSF, IMID, Biomedical sciences, Long, DN Capital, Nicholas J. Pritzker, Pharmaceutical industry, Medical device, Biotechnology, Microbiology, Rheumatology

Members of the IMIDomics Immunology Advisory Board include:

Key Points: 
  • Members of the IMIDomics Immunology Advisory Board include:
    Andr Veillette, M.D.
  • Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.
  • He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.
  • His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses.

OncoResponse Appoints Renowned Immunologists Drs. Miriam Merad and David G. DeNardo to Scientific Advisory Board

Retrieved on: 
Mardi, novembre 9, 2021
Society, Icahn School of Medicine at Mount Sinai, Immunity, View, Macrophage, Cancer, Mount Sinai, National academy, International Union of Immunological Societies, MD, Neoplasm, MD Anderson Cancer Center, International union, Joe DeNardo, Myelocyte, Doctor of Philosophy, Alexandria Real Estate Equities, IUIS, Immunotherapy, Research, Multimedia, Tumor microenvironment, Mount Sinai School, SAB, Washington University School of Medicine, CPI, Twitter, Pathology, LinkedIn, Therapy, National, American Society for Clinical Investigation, Fibrosis, Survival, Patient, NIH, Qatar Investment Authority, Vaccine, Pharmaceutical industry

SEATTLE, Nov. 9, 2021 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced the appointments of Miriam Merad, MD, PhD, and David G. DeNardo, PhD, to the company's scientific advisory board.

Key Points: 
  • SEATTLE, Nov. 9, 2021 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced the appointments of Miriam Merad, MD, PhD, and David G. DeNardo, PhD, to the company's scientific advisory board.
  • "Dr. Merad identified the lineage and role of macrophages in organ function and their contribution in mediating cancer progression.
  • Dr. Merad has authored over 200 peer-reviewed papers and reviews in high profile journals and belongs to several NIH consortia.
  • I'm pleased to join the OncoResponse scientific advisory board at this interesting time for the company," said Dr. DeNardo.